Royal Bank of Canada’s Aoxing Pharmaceutical Company Inc. AXN Stock Holding History

Royal Bank of Canada’s Portfolio AXN Stock Details AXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-145	Closed	–	–	7022
2017 Q1	$0	Hold	145	–	–	﹤0.01%	6995
2016 Q4	$0	Hold	145	–	–	﹤0.01%	6926
2016 Q3	$0	Hold	145	–	–	﹤0.01%	6734
2016 Q2	$0	Buy	+145	New	+$98	﹤0.01%	6687

Other funds holding AXN

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

FWM

Focused Wealth Management Newburgh, New York $1.15B AUM 24.81% 1-Year Est. Return

Royal Bank of Canada's AXN Position: Q2 2017 in Review

Royal Bank of Canada sold out of Aoxing Pharmaceutical Company Inc. (AXN) in Q2 2017, closing a stake of 145 shares.

Royal Bank of Canada first reported a position in AXN in Q2 2016 and held it in 4 quarters. The position peaked at $0 in Q1 2017. 7 funds tracked by Wall St. Rank hold AXN as of Q2 2017.

Royal Bank of Canada reported no remaining Aoxing Pharmaceutical Company Inc. position as of Q2 2017 after selling out during the quarter.
Royal Bank of Canada sold 145 Aoxing Pharmaceutical Company Inc. shares in Q2 2017.
Royal Bank of Canada first reported a position in Aoxing Pharmaceutical Company Inc. in Q2 2016 and held it in 4 quarters.
Royal Bank of Canada's Aoxing Pharmaceutical Company Inc. position peaked at $0 in Q1 2017.
7 funds tracked by Wall St. Rank held Aoxing Pharmaceutical Company Inc. as of Q2 2017.

Based on Royal Bank of Canada's 13F filing for Q2 2017, filed 14 Aug 2017.